Navigation Links
Waters New Biopharmaceutical System Solution Uniquely Unites UPLC/MS Analyses and Workflows Driven by Industry First Scientific Information System
Date:1/10/2011

MILFORD, Mass., Jan. 10, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today introduced its Waters® Biopharmaceutical System Solution at WCBP, the 15th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products in Washington, D.C.  The new Biopharmaceutical System brings together UPLC®/MS characterization technology with UNIFI™ Scientific Information System, an industry first comprehensive software solution that uniquely unites all aspects of biotherapeutic analyses and workflows for high-resolution analytics across the development process continuum.

The combination of UltraPerformance Liquid Chromatography®, mass spectrometry, and bioinformatics technologies results in efficient flow of data and information and conforms to biopharmaceutical quality guidelines and regulations.

The Biopharmaceutical System Solution includes:

  • ACQUITY UPLC® H-Class Bio System featuring a bio-inert flow path and quaternary solvent management with Auto-Blend Plus™ Technology, for flexibility in executing high-resolution bioseparations;
  • Waters Peptide and Protein Separation Technology Columns engineered with the selectivity to leverage the characteristics of biomolecules and QC-tested to ensure consistent results;
  • Xevo® G2 Tof Mass Spectrometer, the most sensitive exact-mass quantitative and qualitative benchtop MS system designed with Engineered Simplicity™;
  • UNIFI Scientific Information System, an interactive workflow-driven data platform for flexible instrument control, advanced data processing and mining and comprehensive reporting, with GxP laboratory compatibility that enables routine deployment throughout your organization.

"Waters is now the first company to offer biopharmaceutical scientists a total system for protein characterization using high-end mass spectrometry that supports good manufacturing practices regulations (GMP) that biopharmaceutical companies are required to comply with," said Jeff Mazzeo, Director of Biopharmaceutical Business Operations for Waters Division. "In addition to being able to operate in a GxP compliant environment, the new Biopharmaceutical System allows customers to extract and share the maximum amount of information.  For example, when a scientist develops a peptide map in the discovery laboratory, all of the methods and reports generated can be shared with colleagues down the line in the quality control (QC) laboratory leading to significant productivity gains. UNIFI is the common platform that allows customers to share information in a much more efficient manner than previously possible."

Focused on task-specific workflow design, the Biopharmaceutical System features automated data processing and simplified results validation.  Leveraging UNIFI's architecture, the intuitive user interface can be configured for the roles and capabilities of the scientists throughout an organization.  Critical to biopharmaceutical organizations is reliance on an analytical system that supports GMP and compliance tools, such as electronic signatures and user authentication, all with underlying secure database technology.  Lastly, this Biopharmaceutical System is scalable to use as a workstation with the ability to expand to workgroup and enterprise deployments.

With the scalability and flexibility built into the system, customers can anticipate the following benefits from the Biopharmaceutical System:

  • Implementing proven UPLC, exact-mass Tof MS, and bioinformatics technologies purposely built for biotherapeutic analysis, the system addresses protein characterization needs today and laboratories' growth plans for the future.
  • Streamlining analytics by standardizing workflows across laboratories, and expedite development decisions and regulatory filings with efficient information synthesis is designed to increase productivity.
  • With the versatility to meet the needs of multiple users in a diverse analytical organization, the UNIFI-based platform enables easier transfer of information between departments, so therapeutics can efficiently move from non-regulated investigations to compliant analyses.
  • Because customers ultimately know best how to meet their regulatory compliance requirements; the Biopharmaceutical System provides a configurable tool to enable customers to deploy analytical technologies with the greatest efficiency.

For more information on the Biopharmaceutical Platform, please visit: http://www.waters.com/waters/nav.htm?cid=10195515

About Waters Corporation (www.waters.com)

For more than 50 years, Waters Corporation (NYSE: WAT) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.5 billion in 2009 and 5,200 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, ACQUITY, UPLC, UltraPerformance LC, Xevo, Auto-Blend Plus, Engineered Simplicity, and UNIFI are trademarks of Waters Corporation.


'/>"/>
SOURCE Waters Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Waters Corporation and UCLA to Convene Leading Life Scientists
2. A warmer future for watersports
3. Waters and DAISO Sign Marketing Agreement for Bulk Process Chromatography Media
4. Waters Ships First Units of SYNAPT G2 Mass Spectrometer
5. First ASMS Hites Award for Outstanding Research Publication Presented to Prof. Alison Ashcroft for Her Use of Waters Synapt HDMS System to Explore Protein Complexes
6. Waters Introduces New SYNAPT G2 with Greater Power, Versatility and Speed Than Any Other High-End Mass Spectrometer
7. Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
8. Waters Corporation Continues to Meet Todays Challenges for Improved Laboratory Operations with New Products at Pittcon 2009
9. USDA Boosts Food Safety Research with Purchase of Waters ACQUITY TQD System
10. XenoTech LLC Offers Drug Industry New Metabolite Profiling Services Following Acquisition of Waters Synapt HDMS System
11. Waters New ACQUITY UPLC Online Community Attracts More Than 1,200 Members in First Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):